<DOC>
	<DOCNO>NCT00375622</DOCNO>
	<brief_summary>Hereditary hemorrhagic telangiectasia ( HHT ) associate recurrent epistaxis 90 % case . Good response hormone treatment document , although use remain controversial . A double-blind placebo-controlled trial estrogen treatment show benefit placebo . The aim study examine efficacy antiestrogenic agent , TAMOXIFEN , treatment HHT-associated epistaxis . The study include 60 patient , 18 year old .</brief_summary>
	<brief_title>Anti-Estrogen Therapy Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial</brief_title>
	<detailed_description>Patients HHT-related epistaxis attend center randomly assign 6 month treatment either Tab . tamoxifen 20 mg daily placebo . The group include men woman age 18 year . A detailed medical history take presentation . All patient examine otolaryngologist trial ass nasal condition telangiectases blood clot airway , nasal oral cavity , body skin . Blood collect blood count measurement clot time liver function onset trial monthly treatment . Patients request complete daily chart describe course epistaxis , female patient refer gynecologic follow-up , include ultrasound . Evaluations conduct month throughout treatment period . The study approve Ethics Committee Rabin Medical Center . All patient sign consent form .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients suffer HHT severe epistaxis Over 18 year old Under 18 year old Pregnancy Treatment anticoagulance Treatment hormone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>HHT</keyword>
	<keyword>Epistaxis</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Hemoglobin</keyword>
</DOC>